Clinical Endocannabinoid Deficiency (CECD)

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
This 2004 study by Ethan Russo, published in the journal Neuroendocrinology, examines the concept of clinical endocannabinoid deficiency and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome and other functional conditions alleviated by clinical cannabis. (more…)